Objective        To determine the effect of glucagon-like peptide-1 (GLP-1) agonist exenatide on the proliferation and migration in breast cancer

colon cancer

and pancreatic cancer cells in vitro.         Methods         Breast cancer cell line MDA-MB-231

colon cancer cell line HCT116 and pancreatic cell line HS766T were selected as experimental subjects. Each type of cells was divided into control group

metformin group and exenatide group. After administration of metformin and exenatide respectively

CCK-8 assay was used for the proliferation detection in each group in 72 h after treatment

and the migration of tumor cells was observed using Transwell chamber assay in 12 h after treatment.         Results        Compared with the control group

the proliferation of MDA-MB-231 cells in exenatide group was significantly inhibited (P0.01)

the proliferation of HCT116 cells were inhibited (P0.05)

and the proliferation of HS766T was not affected (P0.05). Transwell migration assay showed that MDA-MB-231 cell migration was significantly inhibited by exenatide (P0.01)

HCT116 cell migration was also inhibited (P0.05)

but cell migration in HS766T group was significantly increased by exenatide (P0.01).         Conclusion        Exenatide inhibits the proliferation and migration in breast cancer cells and colon cancer cells. It has no effect on the proliferation

but promotes the migration in pancreatic cancer cells. Exenatide exerts different effects on different tumor cells.